BRAF mutations are known to be mutually exclusive with KRAS mutations and Vaughn et al have reported that almost 8% of the CRC subgroup with wild type KRAS gene had BRAF mutations; these patients would receive EGFR inhibitors but would be unresponsive to therapy[8]. Here, EGFR is linked to colorectal carcinoma.